February 2012 – the first report on HDAC (Histone Deacetylase) inhibitors’ regulation of t-PA was published1. The report clearly showed that HDAC inhibitors strongly regulate the production of t-PA.
April 2012 – Cereno Scientific founded by professor Sverker Jern, Niklas Bergh and Pia Larsson. Björn Dahlöf and Jonas Faijerson Säljö were recruited soon after.
GU Ventures AB – a holding company focused on companies in an early development phase spun-out of research at the University of Gothenburg – invested in a new rights issue.
August 2012 – animal studies initiated and the first study in healthy human volunteers began.
May 2014 – data published from an experimental study of myocardial infarction in pigs2 showed that pre-treatment with valproic acid increases the release capacity of t-PA in the coronary arteries.
Autumn 2014 – board strengthened with Catharina Bäärnhielm and Sten R. Sorensen – both having long and extensive experience in drug development, not least in the development and commercialization of drugs for the treatment of cardiovascular diseases.
October 2014 – results published from a study in which healthy people received treatment with valproic acid. The unexpected discovery was that valproic acid also lowers the PAI-1 levels in blood3. PAI-1 is the most important inhibitor of fibrinolysis.
March 2015 – results published from a study of people with a history of heart attack in which valproic acid was shown to lower PAI-1 levels in the blood and increase the release capacity of t-PA4.
July 2015 – approval obtained from the Swedish Medical Products Agency and the Ethics Committee in Gothenburg to begin the third study in humans. The primary objective of this study is to deepen the knowledge of valproic acid’s regulating effects on PAI-1.
September 2015 – board appoints Sten R Sorensen as CEO and Niklas Bergh as Chief Scientific Officer.
November 2015 – board takes decision to start process of raising additional capital and to IPO Cereno Scientific’s share during the first half of 2016.
Catharina Bäärnhielm was elected Chairman and Niklas Bergh as a deputy.
December 2015 – Karin Wåhlander, who has extensive experience in drug development in the area of thrombosis, appointed as Vice President R&D.
During the period 2011 – 2015, approximately 12.2 MSEK was invested in the development work conducted by Cereno Scientific.
January 2016 – agreement signed with Galenica AB regarding development work on a new formulation of valproic acid, to be known as CS1.
So far, Cereno Scientific has conducted experimental preclinical studies and two early human studies.
Currently, the company is focusing on delivering the third clinical study, which is important for the continued development of a unique formulation of CS1.
February & March 2016 – directed share issue of 8.5 MSEK heavily oversubscribed. The issue was not carried out in accordance with the existing shareholders’ preferential rights and was directed to a limited circle of investors. The issue was made as part of the preparations for the listing of the company’s shares on the AktieTorget stock market during the second quarter of 2016.
February 2016 – directed share issue of 2.7 MSEK agreed with Galencia AB. This provided Cereno Scientific with additional development capital, as well as a new strategic shareholder.
- Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression. Larsson et al. 2012.
- Histone deacetylase inhibitor treatment increases coronary t-PA release in a porcine ischemia model. Svennerholm et al. 2014.
- Profibrinolytic effect of the epigenetic modifier valproic acid in man. Saluveer et al. 2014.
- Histone deacetylase inhibition enhances tissue plasminogen activator release capacity in atherosclerotic man. Svennerholm et al. 2015.